Kamada (KMDA) Short-term Investments (2012 - 2026)

Kamada's (KMDA) quarterly Short-term Investments came in at $40.2 million in Q1 2026, up 20318.78% on a QoQ basis from $197000.0 in Q4 2025.

Kamada (KMDA) Short-term Investments (2012 - 2026) Analysis & Trends

Kamada (KMDA) has 15 years of Short-term Investments data on file, last reported at $40.2 million in Q1 2026.

Quarterly Short-term Investments changed N/A year-over-year to $40.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.2 million (changed N/A YoY) and the FY2025 annual result came in at $197000.0, up 302.04% from the prior year.
Short-term Investments grew to $40.2 million in Q1 2026, from $197000.0 in the prior quarter.
In the past five years, Short-term Investments ranged from a high of $40.2 million in Q1 2026 to a low of $4000.0 in Q4 2022.
A 5-year average of $8.1 million and a median of $149000.0 in 2023 frame the typical range for Short-term Investments.
Annual changes were most pronounced in 2022 — Short-term Investments tumbled 100.0% — and 2023, when it surged 3625.0%.
Tracing KMDA's Short-term Investments over 5 years: stood at $4000.0 in 2022, then surged by 3625.0% to $149000.0 in 2023, then plunged by 67.11% to $49000.0 in 2024, then soared by 302.04% to $197000.0 in 2025, then jumped by 20318.78% to $40.2 million in 2026.
The last three Short-term Investments figures came in at $40.2 million (Q1 2026), $197000.0 (Q4 2025), and $49000.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-
2	Teva Pharmaceutical Industries	43.41 Bn	39.75 Bn	2.15 Bn
3	Zoetis	31.83 Bn	30.15 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.77 Bn	22.97 Bn	5.10 Bn
5	United Therapeutics	22.27 Bn	19.61 Bn	683.80 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn
7	Neurocrine Biosciences	15.65 Bn	15.26 Bn	935.80 Mn
8	Elanco Animal Health	11.93 Bn	11.40 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-
10	Kamada	457.71 Mn	428.24 Mn	22.47 Mn

Download Data